(Q53852624)

21 May 2018

title

Basiliximab: efficacy and tolerability in adults and children (English)

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2003.09.098

recombinant fusion proteins

31 March 2024

main subject

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14612000

31 March 2024

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2003.09.098

31 March 2024

author name string

Simulect Multicenter Study Group of Chile

10

1 reference

21 May 2018

A. Mocarquer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14612000

31 March 2024

V. Pinto

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14612000

31 March 2024

E. Buckel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14612000

31 March 2024

E. Lagos

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14612000

31 March 2024

J. Pefaur

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14612000

31 March 2024

K. Ramirez

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14612000

31 March 2024

J. Morales

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14612000

31 March 2024

P. Rosatti

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14612000

31 March 2024

A. Elberg

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14612000

31 March 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

21 May 2018

full work available at URL

https://api.elsevier.com/content/article/PII:S0041134503009837?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2003.09.098

https://api.elsevier.com/content/article/PII:S0041134503009837?httpAccept=text/plain

31 March 2024

1 reference

https://api.crossref.org/works/10.1016/J.TRANSPROCEED.2003.09.098

Transplantation Proceedings

31 March 2024

published in

1 reference

21 May 2018

volume

35

1 reference

21 May 2018

issue

7

1 reference

21 May 2018

page(s)

2518-2519

1 reference

21 May 2018

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.09.098

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.09.098

Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.09.098

Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.09.098

A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.09.098

Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.09.098

Economic analysis of basiliximab in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.09.098

Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.09.098

A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.09.098

A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2003.09.098

7 January 2021

Identifiers

1 reference

21 May 2018

1 reference

21 May 2018